Exclusive special offer and discount title banner vector image

EUROPE DRY EYE DISEASE MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Europe Dry Eye Disease Market by Type (OTC, Prescription) Market by Product (Anti-inflammatory Drugs (Cyclosporine, Corticosteroid, Other Anti-inflammatory Drugs), Artificial Tears, Punctal Plugs, Secretagogues, Other Products) Market by Distribution Channel (Hospital Pharmacies, Independent Pharmacies and Drugstores, Online Pharmacies) by Geography


MARKET OVERVIEW

The Europe dry eye disease market growth is anticipated to progress at a CAGR of 4.79% during the forecast period, 2023-2032, and is predicted to garner a revenue of $2569.11 million by 2032.

The dry eye disease market growth in Europe is accredited to the increasing glaucoma incidences, the growing market consolidation, the surging awareness about the dry eye disease condition, and the rising aging population. Also, the region has robust healthcare with heavy investments by both private and government players. However, the Europe dry eye disease market growth is hindered by the availability of alternative treatments and side effects caused by eye drops.

To Know More About This Report, Request a Free Sample Copy

The Europe dry eye disease market growth evaluation includes the analysis of Italy, the United Kingdom, Poland, Spain, France, Germany, Belgium, and Rest of Europe. In the United Kingdom, the growing awareness about dry eye disease and the rising government support are estimated to drive the analyzed market’s growth. Also, the National Health Service (NHS) offers eye screening programs alongside helpline numbers for dry eye treatment. In addition, the UK conducts different types of research on dry eye disease, which contributes to overall growth prospects. Whereas, in France, the increasing number of treatments and the rising patient population fuel the market growth. 

The Europe dry eye disease market segmentation includes distribution channel, type, and product. The distribution channel segment includes hospital pharmacies, online pharmacies, and independent pharmacies and drugstores.

Retail pharmacies are independent pharmacies with a state license to offer drugs to the general public. Over-the-counter (OTC) medications are among the essential components of this distribution channel. As a result, people are increasingly using retail pharmacies as a one-stop shop for acquiring OTC products. Additionally, such medications’ cost is lower than hospital pharmacies’ medications. This serves as an added incentive for consumers to choose independent pharmacies. 

Further, the retail pharmacy sector facilitates an omnichannel, convenient pharmacy experience. It includes home delivery. Also, there is a growing scope for in-home pharmacy experience, with consumers becoming more convenience-focused and experimenting with digital-first pharmacy entrants, particularly post-COVID-19. Besides, a large number of drugstores and small pharmacies are transitioning from conventional models to tech-enabled models and from in-person pickup to delivery. Such aspects are projected to drive independent pharmacies’ growth. 

Furthermore, the growing prevalence of dry eye disease leads to a rising number of hospital visits, thereby promoting the sales of dry eye disease drugs through hospital pharmacies. Generally, pharmacists collaborate with other pharmacies to buy suppliers. However, in Eastern Europe, wholesalers are the primary supplier of pharmaceuticals. Whereas in Western Europe, hospital pharmacists frequently buy their supplies directly from businesses. 

Additionally, unit-dose supply is typical in a few nations where distribution is largely centralized. Besides, pharmacies also offer services to outpatients, with a third of hospitals utilizing barcode technology for stock control and manual item selection. Large hospitals have more automation than smaller hospitals. 

Some of the eminent market players in the Europe dry eye disease market are Santen Pharmaceutical Co Ltd, Novartis AG, Otsuka Pharmaceutical Co Ltd, OASIS Medical, etc.

Novartis AG is a Swiss-American multinational pharmaceutical company that provides products for gene, cell, cancer, metabolic, and cardio therapies. The product portfolio includes biosimilars, generic medicines, vision care products, ophthalmic pharmaceuticals, etc. The company operates across the Middle East & Africa, the Americas, Europe, and Asia-Pacific, with headquarters in Basel, Switzerland. 

One of its key products, Xiidra® (lifitegrast ophthalmic solution) 5%, is the only prescription treatment approved to treat symptoms and signs of dry eyes by inhibiting inflammation caused by the disease.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments Analyzed
Distribution Channel, Product, Type
Countries AnalyzedItaly, the United Kingdom, Poland, Spain, France, Germany, Belgium, and Rest of Europe
Companies AnalyzedAFT Pharmaceuticals, Alcon, Allergan Plc (Acquired by AbbVie), Bausch Health Companies Inc, Johnson & Johnson, Lumenis, Novaliq GmbH, Novartis AG, OASIS Medical, Otsuka Pharmaceutical Co Ltd, Santen Pharmaceutical Co Ltd, Sentiss Pharma Private Limited, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, VISUfarma

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
    5. MAJOR MARKET FINDINGS
      1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
      2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
      3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
      4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE 
      2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE 
      3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
    2. KEY RESTRAINTS
      1. RISK OF SIDE EFFECTS
      2. SUBSTITUTE THERAPIES
      3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO
  4. KEY ANALYTICS
    1. PARENT MARKET ANALYSIS
    2. KEY MARKET TRENDS
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING
    5. MARKET MATURITY ANALYSIS
    6. MARKET CONCENTRATION ANALYSIS
    7. VALUE CHAIN ANALYSIS
      1. RESEARCH AND DEVELOPMENT
      2. MANUFACTURING
      3. DISTRIBUTORS
      4. POST-SALES MONITORING
  5. MARKET BY TYPE
    1. OTC
    2. PRESCRIPTION
  6. MARKET BY PRODUCT
    1. ANTI-INFLAMMATORY DRUGS
      1. CYCLOSPORINE
      2. CORTICOSTEROID
      3. OTHER ANTI-INFLAMMATORY DRUGS
    2. ARTIFICIAL TEARS
    3. PUNCTAL PLUGS
    4. SECRETAGOGUES
    5. OTHER PRODUCTS
  7. MARKET BY DISTRIBUTION CHANNEL
    1. HOSPITAL PHARMACIES
    2. INDEPENDENT PHARMACIES AND DRUGSTORES
    3. ONLINE PHARMACIES
  8. GEOGRAPHICAL ANALYSIS
    1. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE DRY EYE DISEASE MARKET DRIVERS
      3. EUROPE DRY EYE DISEASE MARKET CHALLENGES
      4. EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS IN EUROPE DRY EYE DISEASE MARKET
      6. COUNTRY ANALYSIS
        1. UNITED KINGDOM
          1. UNITED KINGDOM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 
        2. GERMANY
          1. GERMANY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 
        4. ITALY
          1. ITALY DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
        5. BELGIUM
          1. BELGIUM DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 
        6. SPAIN
          1. SPAIN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
        7. POLAND
          1. POLAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES 
        8. REST OF EUROPE
          1. REST OF EUROPE DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  9. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
      4. BUSINESS EXPANSIONS & DIVESTITURES
    2. COMPANY PROFILES
      1. AFT PHARMACEUTICALS
      2. ALCON
      3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
      4. BAUSCH HEALTH COMPANIES INC
      5. JOHNSON & JOHNSON
      6. LUMENIS
      7. NOVALIQ GMBH
      8. NOVARTIS AG
      9. OASIS MEDICAL
      10. OTSUKA PHARMACEUTICAL CO LTD
      11. SANTEN PHARMACEUTICAL CO LTD
      12. SENTISS PHARMA PRIVATE LIMITED
      13. SUN PHARMACEUTICAL INDUSTRIES LTD
      14. TEVA PHARMACEUTICAL INDUSTRIES LTD
      15. VISUFARMA

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – DRY EYE DISEASE

TABLE 2: EUROPE DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: EUROPE DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 4: EUROPE DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: EUROPE DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 6: EUROPE DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: EUROPE DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 8: EUROPE DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: EUROPE DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 10: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: EUROPE DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 12: EUROPE DRY EYE DISEASE MARKET REGULATORY FRAMEWORK

TABLE 13: KEY PLAYERS OPERATING IN EUROPE DRY EYE DISEASE MARKET

TABLE 14: LIST OF MERGERS & ACQUISITIONS

TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR EUROPE

FIGURE 4: MARKET MATURITY ANALYSIS

FIGURE 5: MARKET CONCENTRATION ANALYSIS

FIGURE 6: VALUE CHAIN ANALYSIS

FIGURE 7: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022

FIGURE 8: EUROPE DRY EYE DISEASE MARKET, BY OTC, 2023-2032 (IN $ MILLION)

FIGURE 9: EUROPE DRY EYE DISEASE MARKET, BY PRESCRIPTION, 2023-2032 (IN $ MILLION)

FIGURE 10: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2022

FIGURE 11: EUROPE DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)

FIGURE 12: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY ANTI-INFLAMMATORY DRUGS, IN 2022

FIGURE 13: EUROPE DRY EYE DISEASE MARKET, BY CYCLOSPORINE, 2023-2032 (IN $ MILLION)

FIGURE 14: EUROPE DRY EYE DISEASE MARKET, BY CORTICOSTEROID, 2023-2032 (IN $ MILLION)

FIGURE 15: EUROPE DRY EYE DISEASE MARKET, BY OTHER ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)

FIGURE 16: EUROPE DRY EYE DISEASE MARKET, BY ARTIFICIAL TEARS, 2023-2032 (IN $ MILLION)

FIGURE 17: EUROPE DRY EYE DISEASE MARKET, BY PUNCTAL PLUGS, 2023-2032 (IN $ MILLION)

FIGURE 18: EUROPE DRY EYE DISEASE MARKET, BY SECRETAGOGUES, 2023-2032 (IN $ MILLION)

FIGURE 19: EUROPE DRY EYE DISEASE MARKET, BY OTHER PRODUCTS, 2023-2032 (IN $ MILLION)

FIGURE 20: EUROPE DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022

FIGURE 21: EUROPE DRY EYE DISEASE MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)

FIGURE 22: EUROPE DRY EYE DISEASE MARKET, BY INDEPENDENT PHARMACIES AND DRUGSTORES, 2023-2032 (IN $ MILLION)

FIGURE 23: EUROPE DRY EYE DISEASE MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)

FIGURE 24: EUROPE DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 25: UNITED KINGDOM DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 26: GERMANY DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 27: FRANCE DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 28: ITALY DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 29: BELGIUM DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 30: SPAIN DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 31: POLAND DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FIGURE 32: REST OF EUROPE DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)

FAQ’s